Biologically stable liquid composition of FVIII, of vWF or of FVIII/vWF complex of human origin
Biologically stable liquid composition of FVIII, of vWF or of FVIII/vWF complex of human origin. The composition comprises a concentrate of FVIII, of vWF or of FVIII/vWF complex of human origin with a chelating agent for metals, a specific ligand and preferably a protease inhibitor.
1 . Biologically stable liquid composition of FVIII or of vWF or of FVIII/vWF complex of human origin, characterised in that it comprises a concentrate of FVIII or of vWF or of FVIII/vWF complex of human origin with a chelating agent for metals, a specific ligand and preferably a protease inhibitor.
2 . Biologically stable liquid composition of FVIII or of vWF or of FVIII/vWF complex of human origin according to claim 1 , characterised in that the chelating agent for metals is used at a concentration of 2-100 mmol/l of the concentrate.
3 . Biologically stable liquid composition of FVIII or of vWF or of FVIII/vWF complex of human origin according to claim 1 , characterised in that the chelating agent for metals is EDTA.
4 . Biologically stable liquid composition of FVIII or of vWF or of FVIII/vWF complex of human origin according to claim 1 , characterised in that the chelating agent for metals is EDTACaNa 2 (sodium and calcium salt of EDTA).
5 . Biologically stable liquid composition of FVIII or of vWF or of FVIII/vWF complex of human origin, according to claim 1 , characterised in that the ligand is included at a concentration of 0.1-10 U/ml of the concentrate.
6 . Biologically stable liquid composition of FVIII or of vWF or of FVIII/vWF complex of human origin according to claim 1 , characterised in that the ligand is heparin.
7 . Biologically stable liquid composition of FVIII or of vWF or of FVIII/vWF complex of human origin according to claim 1 , characterised in that the ligand is sodium heparin.
8 . Biologically stable liquid composition of FVIII or of vWF or of FVIII/vWF complex of human origin according to claim 1 , characterised in that the protease inhibitor is present at a concentration greater than 0.01 IU/IU FVIII.
9 . Biologically stable liquid composition of FVIII or of vWF or of FVIII/vWF complex of human origin according to claim 8 , characterised in that the protease inhibitor is present at a concentration of 0.01-1 IU/IU FVIII.
10 . Biologically stable liquid composition of FVIII or of vWF or of FVIII/vWF complex of human origin according to claim 1 , characterised in that the protease inhibitor is a serine protease inhibitor (serpin).
11 . Biologically stable liquid composition of FVIII or of vWF or of FVIII/vWF complex of human origin according to claim 10 , characterised in that the serine protease inhibitor is antithrombin.